[{"id":"00dab510-ce67-4a8e-8ef1-dc0dba1fc50e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00759785","created_at":"2021-01-18T02:52:13.209Z","updated_at":"2024-07-02T16:37:07.885Z","phase":"Phase 1","brief_title":"A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013)","source_id_and_acronym":"NCT00759785","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dalotuzumab (MK 0646)"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 09/30/2008","start_date":" 09/30/2008","primary_txt":" Primary completion: 02/17/2010","primary_completion_date":" 02/17/2010","study_txt":" Completion: 02/17/2010","study_completion_date":" 02/17/2010","last_update_posted":"2018-08-15"},{"id":"b0fef793-7b81-42b4-ba49-db123c09fe43","acronym":"","url":"https://clinicaltrials.gov/study/NCT00614393","created_at":"2021-01-18T02:16:58.601Z","updated_at":"2024-07-02T16:37:08.137Z","phase":"Phase 2","brief_title":"Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)","source_id_and_acronym":"NCT00614393","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS wild-type • KRAS expression","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS wild-type • KRAS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • irinotecan • dalotuzumab (MK 0646)"],"overall_status":"Completed","enrollment":" Enrollment 558","initiation":"Initiation: 12/24/2007","start_date":" 12/24/2007","primary_txt":" Primary completion: 06/01/2010","primary_completion_date":" 06/01/2010","study_txt":" Completion: 03/07/2012","study_completion_date":" 03/07/2012","last_update_posted":"2018-08-08"},{"id":"a029591e-46da-4354-9f40-6f34e9c1d8c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01234857","created_at":"2021-01-18T04:58:05.618Z","updated_at":"2024-07-02T16:37:21.547Z","phase":"Phase 2","brief_title":"A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)","source_id_and_acronym":"NCT01234857","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • Taltorvic (ridaforolimus) • dalotuzumab (MK 0646)"],"overall_status":"Completed","enrollment":" Enrollment 115","initiation":"Initiation: 09/17/2010","start_date":" 09/17/2010","primary_txt":" Primary completion: 10/15/2013","primary_completion_date":" 10/15/2013","study_txt":" Completion: 10/15/2013","study_completion_date":" 10/15/2013","last_update_posted":"2017-05-31"}]